Table 1.
Clinical characteristics of the studied population.
| All Patients (n = 70) |
d-CTEPH Group (n = 54) |
p-CTEPH Group (n = 16) |
p | |
|---|---|---|---|---|
| Age (years) | 64.5 (52–73) | 62.5 (48–70) | 73 (62–82) | 0.008 |
| Females (%) | 37 (53%) | 29 (54%) | 8 (50%) | 0.5 |
| BMI (kg/m2) | 25.8 (23.3–28.5) | 25.5 (23.4–28.1) | 26.4 (23.0–33.3) | 0.35 |
| History of PE | 52 (74%) | 41 (76%) | 11 (69%) | 0.39 |
| History of DVT | 24 (34%) | 17 (31%) | 7 (44%) | 0.27 |
| Comorbidities | ||||
| Coronary heart disease | 13 (19%) | 8 (15%) | 5 (31%) | 0.13 |
| Systemic hypertension | 33 (47%) | 24 (44%) | 9 (56%) | 0.29 |
| Type II diabetes | 11 (16%) | 9 (17%) | 2 (13%) | 0.51 |
| COPD | 6 (9%) | 4 (7%) | 2 (13%) | 0.42 |
| Chronic kidney disease (eGFR < 60 mL/min) | 12 (17%) | 6 (11%) | 6 (38%) | 0.02 |
| Atrial fibrillation/flutter | 12 (17%) | 9 (17%) | 3 (19%) | 0.55 |
| Pacemaker leads or ventriculoatrial shunts | 6 (9%) | 6 (11%) | 0 | 0.19 |
| Concomitant therapy | ||||
| Sildenafil | 20 (29%) | 15 (28%) | 5 (31%) | 0.51 |
| Riociguat | 42 (60%) | 31 (57%) | 11 (69%) | 0.30 |
| Prostanoids | 1 (1%) | 1 (2%) | 0 | - |
| PAH-like monotherapy | 61 (87%) | 45 (83%) | 16 (100%) | 0.08 |
| PAH-like combination therapy | 1 (1%) | 1(2%) | 0 | - |
| VKA | 22 (31%) | 17 (31%) | 5 (31%) | 0.9 |
| LMWH | 8 (11%) | 5 (9%) | 3 (19%) | 0.26 |
| DOAC | 40 (57%) | 32 (59%) | 8 (50%) | 0.35 |
BMI—body mass index; PE—pulmonary embolism; DVT—deep vein thrombosis; COPD—chronic obstructive pulmonary disease; eGFR—estimated glomerular filtration rate; PAH—pulmonary arterial hypertension; VKA—vitamin K antagonists; LMWH–low molecular weight heparin; DOAC—direct oral anticoagulants.